Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors

Published:2022-06 Issue:6 Volume:85 Page:687-692
ISSN:1726-4901
Container-title:Journal of the Chinese Medical Association
language:en
Short-container-title:

Author:

Lai Cheng-Lun,Chen Tien-Hua,Chang Peter Mu-Hsin,Tai Shyh-Kuan,Chu Pen-Yuan,Yang Muh-Hwa

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference16 articles.

1. Head and neck cancer.;Argiris;Lancet,2008

2. Platinum-based chemotherapy plus cetuximab in head and neck cancer.;Vermorken;N Engl J Med,2008

3. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.;Burtness;Lancet,2019

4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.;Cohen;Lancet,2019

5. Nivolumab for recurrent squamous-cell carcinoma of the head and neck.;Ferris;N Engl J Med,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part IV;Journal of the Chinese Medical Association;2023-11-22

2. Front-line chemo-immunotherapy for treating epithelial ovarian cancer: Part I CA125 and anti-CA125;Taiwanese Journal of Obstetrics and Gynecology;2023-11

3. Winners of the 2022 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I;Journal of the Chinese Medical Association;2023-07-18